search
Back to results

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU)

Primary Purpose

Lymphoma, Non-Hodgkin

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Nivolumab
Rituximab
Gemcitabine
Oxaliplatin
Sponsored by
Universität des Saarlandes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma, Non-Hodgkin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with first relapse or progression of an aggressive Non-Hodgkin's lymphoma
  • all patient >65 years of age or > 18 years if not eligible for neither autologous nor allogeneic stem cell transplantation
  • all patient >65 years of age or older than 18 years if HCT-CI score > 2 or patients who underwent prior autologous stem cell transplantation and are not eligible for allogeneic stem cell Transplantation
  • All risk groups (IPI 0 to 5)
  • Diagnosis of aggressive Non-Hodgkin's lymphoma, based on an excisional biopsy of a lymph node or on an appropriate sample of a lymph node or of an extranodal involvement at initial diagnosis or relapse or Progression. The entities treated in the study will be based on the WHO 2017 classification.
  • ECOG 0 - 2
  • only one prior chemotherapy regimen including an anthracycline. The last cytotoxic drug must be given at least four weeks before entering the study. Rituximab must be part of the first-line regimen in case of B-cell lymphoma (except for primary CD20- negative lymphoma). Patients may have received prior radiation therapy as part of their first-line therapy
  • Men who are sexually active with women of childbearing potential (WOCBP) must not father a child during and up to 6 months after GemOx and up to 12 months after Rituximab and/or Nivolumab. They are advised to do cryoconservation of sperm prior to treatment.
  • Written informed consent of the patient
  • Patient must be covered by social security system

Exclusion Criteria:

  • Already initiated lymphoma therapy after first relapse or progression
  • Serious accompanying disorder or impaired organ function
  • WBC < 2.5 G/l, Neutrophils < 2 G/l, Platelets < 100 G/l
  • Prolongation of QTc interval > 450 ms, demonstrated in one electrocardiogram (done as triplicate). This does not apply for patients with a block of the right and/or left bundle branch.
  • Family history for Long QT-Syndrome
  • active, known or suspected autoimmune disease
  • no requirement for immunosuppressive doses of systemic corticosteroids
  • Chronic active hepatitis B or C
  • HIV-infection
  • Patients with a severe immunodeficiency
  • Previous therapy with Nivolumab,Gemcitabine or Oxaliplatin
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancer
  • CNS involvement of lymphoma
  • Persistent neuropathy grade >2
  • Pregnancy or breast-feeding women
  • Women of childbearing potential
  • Active serious infections not controlled by oral and/or intravenous antibiotics or anti-fungal medication
  • Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities
  • Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma, Mantle cell lymphoma, Burkitt lymphoma, adult T-cell leukemia/lymphoma.
  • Persons not able to understand the impact, nature, risks and consequences of the trial (including language barrier)
  • Persons not agreeing to the transmission of their pseudonymous data
  • Persons depending on sponsor or investigator
  • Persons from highly protected Groups
  • Allergies and Adverse Drug Reaction History to study drug components
  • Participation in another clinical trial with drug intervention within 4 weeks prior to start of the first cycle and during the study. However, participation in a clinical trial of firstline therapy of lymphoma is allowed.

Sites / Locations

  • Landeskrankenhaus Feldkirch
  • Innsbruck University Hospital
  • Kepler Universitätsklinikum GmbH- Med. Campus III
  • Ordensklinikum Linz - Elisabethinen
  • Ordensklinikum Linz - Krankenhaus der Barmherzigen Schwestern Linz
  • Paracelsus Medical University Salzburg
  • Klinikum Wels-Grieskirchen GmbH
  • Universitätsklinik für Innere Medizin I, AKH Wien
  • INSTITUT JULES BORDET -Hematology
  • UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology
  • UNIVERSITAIR ZIEKENHUIS GENT - Hematology
  • CHU DE LIEGE - Hematology
  • UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology
  • CHU Côte de Nacre - Service Hématologie Clinique
  • Hôpital Henri Mondor - Unité "Hémopathies Lymphoïdes" - HDJ 11è
  • CHU Dijon - Hôpital d'Enfants - Hématologie Clinique
  • CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique
  • CH Départemental Vendée - Onco-Hématologie
  • CHRU de Lille - Hôpital Claude Hurriez
  • CHU de Montpellier - Hématologie Clinique
  • CHU de Nantes - Hôtel Dieu - Hématologie
  • Hôpital Saint Louis - Onco-Hématologie
  • Hôpital Necker - Hématologie Clinique
  • CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie
  • CHU Lyon Sud - Hématologie
  • Hôpital Pontchaillou - Hématologie
  • Centre Henri Becquerel - Hématologie
  • Institut de Cancèrologie Lucien Neuwirth
  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
  • IUCT Oncopole - Hématologie
  • CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne
  • Sozialstiftung Bamberg
  • Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie
  • Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie
  • Klinikum Chemnitz, Innere Medizin III
  • BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
  • Gemeinschaftspraxis Dres. Mohm, Prange-Krex
  • St. Antonius-Hospital Eschweiler, Klinik für Hämatologie
  • Universitätsklinikum Essen, Klinik für Hämatologie
  • Universitätsmedizin Göttingen, Klinik für Hämatologie
  • Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV
  • Universitätsklinikum Hamburg-Eppendorf
  • Universitätsklinikum des Saarlandes, Innere Med. I
  • Westpfalz-Klinikum, Klinik für Innere Medizin I
  • St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2
  • Uni Gießen und Marburg, Klinik für Hämatologie
  • Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
  • Klinikum der Universität München, Med. Klinik und Poliklinik III
  • Universitätsklinikum Münster
  • Brüderkrankenhaus St. Josef Paderborn
  • Universitätsklinikum Regensburg, Klinik für Innere Medizin III
  • Universitätsmedizin Rostock, Klinik für Hämatologie
  • Klinikum Stuttgart, Klinik für Hämatologie
  • Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I
  • Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung
  • Universitätsklinikum Tübingen, Innere Medizin II
  • Uniklinikum Ulm, Klinik für Innere Medizin III
  • Schwarzwald-Baar Klinikum, Innere Medizin II
  • The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation
  • MC Alkmaar
  • AMC Academisch Medisch Centrum
  • VUMC
  • Reinier de Graaf Gasthuis
  • Maxima Medisch Centrum
  • MC Leeuwarden Zuid
  • Antonius Ziekenhuis
  • Radboudumc Nijmegen
  • Szpital Specjalistyczny w Brozowie
  • Oncologic Center
  • Uniwersyteckie Centrum Kliniczne
  • Swietorkrzyskie Centrum Oncologii
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
  • Samodzielny Publiczny Szpital Kliniczny Nr. 1
  • Oncologic Center
  • Marie Sklodowska-Curie Institute and Oncology
  • Wojskowy Instytut Medyczny
  • Instituto Português Oncologia - Hematology

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

(R)-GemOx

Nivo-(R)-GemOx

Arm Description

eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)

eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first

Outcomes

Primary Outcome Measures

PFS
Progression free survival

Secondary Outcome Measures

CR rate
complete response rate
PR rate
partial response rate
ORR rate
overall response rate
Duration of response
Duration of response
Primary Progression rate
Rate of Primary progression
Treatment related deaths rate
Rate of Treatment related deaths
Relapse rate
Rate of relapses
EFS
Event free survival
OS
Overall survival
Toxicities: rates and grades of adverse events
Toxicity: Rates and grades of toxicities will be determined according to CTC-v4.03
Protocol adherence according to number of given chemotherapy cycles
Protocol adherence will be determined according to number of chemotherapy cycles
Protocol adherence according to duration of given chemotherapy cycles
Protocol adherence will be determined according to duration of chemotherapy cycles
Protocol adherence according to cumulative dose of immunochemotherapy given
Protocol adherence will be determined according to cumulative dose of immunochemotherapy given
Protocol adherence according to relative dose of immunochemotherapy given
Protocol adherence will be determined according to relative dose of immunochemotherapy given
QoL
Quality of Life (QoL) will be assessed by the EQ-5D-5L questionnaire
Biological Parameters according to PD-L1 expression alterations
Outcome assessment of response according to PD-L1 expression alterations
Biological Parameters according to PD-1 expression
Outcome assessment of response according to PD-1 expression
Biological Parameters according to cell of origin
Outcome assessment of response according to cell of origin
Biological Parameters according to 9p24.1 alterations
Outcome assessment of response according to 9p24.1 alterations

Full Information

First Posted
September 16, 2017
Last Updated
May 22, 2023
Sponsor
Universität des Saarlandes
Collaborators
Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig
search

1. Study Identification

Unique Protocol Identification Number
NCT03366272
Brief Title
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
Acronym
NIVEAU
Official Title
Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 5, 2017 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
November 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universität des Saarlandes
Collaborators
Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma
Detailed Description
International, multicentre, randomised, open-label, treatment optimisation study, preceded by safety run-in phases conducted for B-cell and T-cell lymphoma separately.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Non-Hodgkin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
348 (Actual)

8. Arms, Groups, and Interventions

Arm Title
(R)-GemOx
Arm Type
Active Comparator
Arm Description
eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
Arm Title
Nivo-(R)-GemOx
Arm Type
Experimental
Arm Description
eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Intervention Description
eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
Intervention Type
Drug
Intervention Name(s)
Rituximab
Intervention Description
eight cycles of R-GemOx in 2-wk intervals
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
eight cycles of (R)-GemOx in 2-wk intervals
Intervention Type
Device
Intervention Name(s)
Oxaliplatin
Intervention Description
eight cycles of (R)-GemOx in 2-wk intervals
Primary Outcome Measure Information:
Title
PFS
Description
Progression free survival
Time Frame
1 year
Secondary Outcome Measure Information:
Title
CR rate
Description
complete response rate
Time Frame
4-6 weeks after cycle 8 (each cycle is 14 days)
Title
PR rate
Description
partial response rate
Time Frame
4-6 weeks after cycle 8 (each cycle is 14 days)
Title
ORR rate
Description
overall response rate
Time Frame
4-6 weeks after cycle 8 (each cycle is 14 days)
Title
Duration of response
Description
Duration of response
Time Frame
up to 2 years after inclusion of last patient
Title
Primary Progression rate
Description
Rate of Primary progression
Time Frame
up to 2 years after inclusion of last patient
Title
Treatment related deaths rate
Description
Rate of Treatment related deaths
Time Frame
up to 2 years after inclusion of last patient
Title
Relapse rate
Description
Rate of relapses
Time Frame
up to 2 years after inclusion of last patient
Title
EFS
Description
Event free survival
Time Frame
up to 2 years after inclusion of last patient
Title
OS
Description
Overall survival
Time Frame
up to 2 years after inclusion of last patient
Title
Toxicities: rates and grades of adverse events
Description
Toxicity: Rates and grades of toxicities will be determined according to CTC-v4.03
Time Frame
up to 2 years after inclusion of last patient
Title
Protocol adherence according to number of given chemotherapy cycles
Description
Protocol adherence will be determined according to number of chemotherapy cycles
Time Frame
up to 2 years after inclusion of last patient
Title
Protocol adherence according to duration of given chemotherapy cycles
Description
Protocol adherence will be determined according to duration of chemotherapy cycles
Time Frame
up to 2 years after inclusion of last patient
Title
Protocol adherence according to cumulative dose of immunochemotherapy given
Description
Protocol adherence will be determined according to cumulative dose of immunochemotherapy given
Time Frame
up to 2 years after inclusion of last patient
Title
Protocol adherence according to relative dose of immunochemotherapy given
Description
Protocol adherence will be determined according to relative dose of immunochemotherapy given
Time Frame
up to 2 years after inclusion of last patient
Title
QoL
Description
Quality of Life (QoL) will be assessed by the EQ-5D-5L questionnaire
Time Frame
up to 1 year after inclusion of last patient
Title
Biological Parameters according to PD-L1 expression alterations
Description
Outcome assessment of response according to PD-L1 expression alterations
Time Frame
up to 2 years after inclusion of last patient
Title
Biological Parameters according to PD-1 expression
Description
Outcome assessment of response according to PD-1 expression
Time Frame
up to 2 years after inclusion of last patient
Title
Biological Parameters according to cell of origin
Description
Outcome assessment of response according to cell of origin
Time Frame
up to 2 years after inclusion of last patient
Title
Biological Parameters according to 9p24.1 alterations
Description
Outcome assessment of response according to 9p24.1 alterations
Time Frame
up to 2 years after inclusion of last patient

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with first relapse or progression of an aggressive Non-Hodgkin's lymphoma all patient >65 years of age or > 18 years if not eligible for neither autologous nor allogeneic stem cell transplantation all patient >65 years of age or older than 18 years if HCT-CI score > 2 or patients who underwent prior autologous stem cell transplantation and are not eligible for allogeneic stem cell Transplantation All risk groups (IPI 0 to 5) Diagnosis of aggressive Non-Hodgkin's lymphoma, based on an excisional biopsy of a lymph node or on an appropriate sample of a lymph node or of an extranodal involvement at initial diagnosis or relapse or Progression. The entities treated in the study will be based on the WHO 2017 classification. ECOG 0 - 2 only one prior chemotherapy regimen including an anthracycline. The last cytotoxic drug must be given at least four weeks before entering the study. Rituximab must be part of the first-line regimen in case of B-cell lymphoma (except for primary CD20- negative lymphoma). Patients may have received prior radiation therapy as part of their first-line therapy Men who are sexually active with women of childbearing potential (WOCBP) must not father a child during and up to 6 months after GemOx and up to 12 months after Rituximab and/or Nivolumab. They are advised to do cryoconservation of sperm prior to treatment. Written informed consent of the patient Patient must be covered by social security system Exclusion Criteria: Already initiated lymphoma therapy after first relapse or progression Serious accompanying disorder or impaired organ function WBC < 2.5 G/l, Neutrophils < 2 G/l, Platelets < 100 G/l Prolongation of QTc interval > 450 ms, demonstrated in one electrocardiogram (done as triplicate). This does not apply for patients with a block of the right and/or left bundle branch. Family history for Long QT-Syndrome active, known or suspected autoimmune disease no requirement for immunosuppressive doses of systemic corticosteroids Chronic active hepatitis B or C HIV-infection Patients with a severe immunodeficiency Previous therapy with Nivolumab,Gemcitabine or Oxaliplatin Patients with a "currently active" second malignancy other than non-melanoma skin cancer CNS involvement of lymphoma Persistent neuropathy grade >2 Pregnancy or breast-feeding women Women of childbearing potential Active serious infections not controlled by oral and/or intravenous antibiotics or anti-fungal medication Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma, Mantle cell lymphoma, Burkitt lymphoma, adult T-cell leukemia/lymphoma. Persons not able to understand the impact, nature, risks and consequences of the trial (including language barrier) Persons not agreeing to the transmission of their pseudonymous data Persons depending on sponsor or investigator Persons from highly protected Groups Allergies and Adverse Drug Reaction History to study drug components Participation in another clinical trial with drug intervention within 4 weeks prior to start of the first cycle and during the study. However, participation in a clinical trial of firstline therapy of lymphoma is allowed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerhard Held, Prof
Organizational Affiliation
Universität des Saarlandes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Landeskrankenhaus Feldkirch
City
Feldkirch
Country
Austria
Facility Name
Innsbruck University Hospital
City
Innsbruck
Country
Austria
Facility Name
Kepler Universitätsklinikum GmbH- Med. Campus III
City
Linz
Country
Austria
Facility Name
Ordensklinikum Linz - Elisabethinen
City
Linz
Country
Austria
Facility Name
Ordensklinikum Linz - Krankenhaus der Barmherzigen Schwestern Linz
City
Linz
Country
Austria
Facility Name
Paracelsus Medical University Salzburg
City
Salzburg
Country
Austria
Facility Name
Klinikum Wels-Grieskirchen GmbH
City
Wels
Country
Austria
Facility Name
Universitätsklinik für Innere Medizin I, AKH Wien
City
Wien
Country
Austria
Facility Name
INSTITUT JULES BORDET -Hematology
City
Brüssel
Country
Belgium
Facility Name
UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology
City
Brüssel
Country
Belgium
Facility Name
UNIVERSITAIR ZIEKENHUIS GENT - Hematology
City
Gent
Country
Belgium
Facility Name
CHU DE LIEGE - Hematology
City
Liège
Country
Belgium
Facility Name
UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology
City
Yvoir
Country
Belgium
Facility Name
CHU Côte de Nacre - Service Hématologie Clinique
City
Caen
Country
France
Facility Name
Hôpital Henri Mondor - Unité "Hémopathies Lymphoïdes" - HDJ 11è
City
Créteil Cedex
Country
France
Facility Name
CHU Dijon - Hôpital d'Enfants - Hématologie Clinique
City
Dijon
Country
France
Facility Name
CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique
City
Grenoble
Country
France
Facility Name
CH Départemental Vendée - Onco-Hématologie
City
La Roche-sur-Yon
Country
France
Facility Name
CHRU de Lille - Hôpital Claude Hurriez
City
Lille
Country
France
Facility Name
CHU de Montpellier - Hématologie Clinique
City
Montpellier
Country
France
Facility Name
CHU de Nantes - Hôtel Dieu - Hématologie
City
Nantes
Country
France
Facility Name
Hôpital Saint Louis - Onco-Hématologie
City
Paris cedex 20
Country
France
Facility Name
Hôpital Necker - Hématologie Clinique
City
Paris
Country
France
Facility Name
CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie
City
Pessac
Country
France
Facility Name
CHU Lyon Sud - Hématologie
City
Pierre-Bénite
Country
France
Facility Name
Hôpital Pontchaillou - Hématologie
City
Rennes
Country
France
Facility Name
Centre Henri Becquerel - Hématologie
City
Rouen
Country
France
Facility Name
Institut de Cancèrologie Lucien Neuwirth
City
Saint-Priest-en-Jarez
ZIP/Postal Code
42271
Country
France
Facility Name
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
City
Strasbourg
Country
France
Facility Name
IUCT Oncopole - Hématologie
City
Toulouse
Country
France
Facility Name
CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne
City
Vandoeuvre-les-Nancy
Country
France
Facility Name
Sozialstiftung Bamberg
City
Bamberg
Country
Germany
Facility Name
Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie
City
Berlin
Country
Germany
Facility Name
Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie
City
Berlin
Country
Germany
Facility Name
Klinikum Chemnitz, Innere Medizin III
City
Chemnitz
Country
Germany
Facility Name
BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
City
Dresden
Country
Germany
Facility Name
Gemeinschaftspraxis Dres. Mohm, Prange-Krex
City
Dresden
Country
Germany
Facility Name
St. Antonius-Hospital Eschweiler, Klinik für Hämatologie
City
Eschweiler
Country
Germany
Facility Name
Universitätsklinikum Essen, Klinik für Hämatologie
City
Essen
Country
Germany
Facility Name
Universitätsmedizin Göttingen, Klinik für Hämatologie
City
Göttingen
Country
Germany
Facility Name
Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV
City
Haale
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
Country
Germany
Facility Name
Universitätsklinikum des Saarlandes, Innere Med. I
City
Homburg
Country
Germany
Facility Name
Westpfalz-Klinikum, Klinik für Innere Medizin I
City
Kaiserslautern
Country
Germany
Facility Name
St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2
City
Karlsruhe
Country
Germany
Facility Name
Uni Gießen und Marburg, Klinik für Hämatologie
City
Marburg
Country
Germany
Facility Name
Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
City
Mutlangen
Country
Germany
Facility Name
Klinikum der Universität München, Med. Klinik und Poliklinik III
City
München
Country
Germany
Facility Name
Universitätsklinikum Münster
City
Münster
Country
Germany
Facility Name
Brüderkrankenhaus St. Josef Paderborn
City
Paderborn
Country
Germany
Facility Name
Universitätsklinikum Regensburg, Klinik für Innere Medizin III
City
Regensburg
Country
Germany
Facility Name
Universitätsmedizin Rostock, Klinik für Hämatologie
City
Rostock
Country
Germany
Facility Name
Klinikum Stuttgart, Klinik für Hämatologie
City
Stuttgart
Country
Germany
Facility Name
Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I
City
Trier
Country
Germany
Facility Name
Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung
City
Trier
Country
Germany
Facility Name
Universitätsklinikum Tübingen, Innere Medizin II
City
Tübingen
Country
Germany
Facility Name
Uniklinikum Ulm, Klinik für Innere Medizin III
City
Ulm
Country
Germany
Facility Name
Schwarzwald-Baar Klinikum, Innere Medizin II
City
Villingen-Schwenningen
Country
Germany
Facility Name
The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation
City
Ramat Gan
Country
Israel
Facility Name
MC Alkmaar
City
Alkmaar
Country
Netherlands
Facility Name
AMC Academisch Medisch Centrum
City
Amsterdam
Country
Netherlands
Facility Name
VUMC
City
Amsterdam
Country
Netherlands
Facility Name
Reinier de Graaf Gasthuis
City
Delft
Country
Netherlands
Facility Name
Maxima Medisch Centrum
City
Eindhoven
Country
Netherlands
Facility Name
MC Leeuwarden Zuid
City
Leeuwarden
Country
Netherlands
Facility Name
Antonius Ziekenhuis
City
Nieuwegein
Country
Netherlands
Facility Name
Radboudumc Nijmegen
City
Nijmegen
Country
Netherlands
Facility Name
Szpital Specjalistyczny w Brozowie
City
Brzozów
Country
Poland
Facility Name
Oncologic Center
City
Bydgoszcz
Country
Poland
Facility Name
Uniwersyteckie Centrum Kliniczne
City
Gdańsk
Country
Poland
Facility Name
Swietorkrzyskie Centrum Oncologii
City
Kielce
Country
Poland
Facility Name
Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
City
Kraków
Country
Poland
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr. 1
City
Lublin
Country
Poland
Facility Name
Oncologic Center
City
Tomaszów Mazowiecki
Country
Poland
Facility Name
Marie Sklodowska-Curie Institute and Oncology
City
Warsaw
Country
Poland
Facility Name
Wojskowy Instytut Medyczny
City
Warszawa
Country
Poland
Facility Name
Instituto Português Oncologia - Hematology
City
Lisboa
Country
Portugal

12. IPD Sharing Statement

Learn more about this trial

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

We'll reach out to this number within 24 hrs